Ibrolipim

Drug Profile

Ibrolipim

Alternative Names: NO 1886; OPF 009

Latest Information Update: 12 Feb 2008

Price : $50

At a glance

  • Originator Otsuka Pharmaceutical
  • Developer TAP Pharmaceutical Products
  • Class Antihyperglycaemics; Antihyperlipidaemics; Obesity therapies; Small molecules
  • Mechanism of Action Lipoprotein lipase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Diabetic complications; Hypertriglyceridaemia; Low HDL cholesterol; Nephrotic syndrome; Obesity

Most Recent Events

  • 08 Mar 2004 No development reported - Phase-II for Obesity in Japan (unspecified route)
  • 08 Mar 2004 No development reported - Phase-II for Low HDL cholesterol in Japan (unspecified route)
  • 08 Mar 2004 No development reported - Phase-II for Hypertriglyceridaemia in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top